Behçet’s Syndrome is a rare, chronic, and multi-system inflammatory disorder characterized by oral and genital ulcers, skin lesions, uveitis, arthritis, and vascular, central nervous system and gastrointestinal involvement.1,2 The condition leads to recurrent oral ulcers which can be painful and lead to a reduced quality-of-life (QOL).1,2 Apremilast is an oral phosphodiesterase-4 inhibitor that modulates several inflammatory pathways and has demonstrated efficacy in the reduction of oral ulcers in a phase 2 study (NCT00866359). However, this preliminary study was not powered to assess long-term efficacy, the effect on other manifestations of Behçet’s syndrome, or the risk of uncommon serious adverse events.1
The preliminary results from the apremilast vs placebo (RELIEF study) for Behçet’s Syndrome were presented at the American Academy of Dermatology 2018 in San Diego and are represented below.
To determine the ability apremilast to reduce the number of oral ulcers in patients with Behçet’s Syndrome over a 64-week period compared to placebo.
Type of study (NCT02307513)3
Primary Outcome Measures
Secondary Outcome Measures
Primary endpoints or outcomes
Secondary endpoints or outcomes
Present disclosure: The presenter has reported that no relationships exist relevant to the contents of this presentation.
Written by: Debbie Anderson, PhD
Reviewed by: Victor Desmond Mandel, MD